$1.75
2.78% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US88875G1013
Symbol
TLSA

Tiziana Life Sciences PLC Sponsored ADR Stock price

$1.75
-0.42 19.35% 1M
+0.18 11.47% 6M
+1.05 151.36% YTD
+0.84 92.31% 1Y
+1.09 166.16% 3Y
-1.10 38.63% 5Y
+0.10 6.21% 10Y
+0.10 6.21% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.05 2.78%
ISIN
US88875G1013
Symbol
TLSA
Industry

Key metrics

Basic
Market capitalization
$200.6m
Enterprise Value
$193.5m
Net debt
positive
Cash
$7.3m
Shares outstanding
118.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
21.8
Financial Health
Equity Ratio
34.9%
Return on Equity
-
ROCE
-200.8%
ROIC
-439.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-18.3m | -
EBIT
$-18.5m | $-23.1m
Net Income
$-12.8m | $-21.8m
Free Cash Flow
$-8.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-16.7% | -
EBIT
-16.9% | -
Net Income
6.5% | -
Free Cash Flow
-123.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.1
FCF per Share
$-0.1
Short interest
1.6%
Employees
9
Rev per Employee
-
Show more

Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Tiziana Life Sciences PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from Tiziana Life Sciences PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 5.90 5.90
20% 20%
-
-18 -18
17% 17%
-
- Depreciation and Amortization 0.15 0.15
50% 50%
-
EBIT (Operating Income) EBIT -18 -18
17% 17%
-
Net Profit -13 -13
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tiziana Life Sciences PLC Sponsored ADR Stock News

Positive
Seeking Alpha
8 days ago
Tiziana Life Sciences' Foralumab intranasal anti-CD3 targets the Treg–microglia axis. However, their intranasal delivery makes them unique and patient-friendly. Foralumab has a Phase 2 for SPMS, a Phase 2a for MSA, and a Phase 2 for AD and ALS is planned. Early data show microglial PET reductions and stability in expanded access. Its bull case hinges on biomarkers against neuroinflammation.
Neutral
GlobeNewsWire
10 days ago
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025.
Positive
Proactive Investors
about one month ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday it has been invited to present at a major biotechnology conference in Riyadh, underscoring Saudi Arabia's push to position itself as a global hub for life sciences research and investment. The Nasdaq-listed biotech will attend the Life Science Innovation Forum, a two-day event hosted Oct. 1–2 at the King Saud bin Abdulaziz University for Heal...
More Tiziana Life Sciences PLC Sponsored ADR News

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Mr. Elrifi
Employees 9
Founded 1998
Website www.tizianalifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today